A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1609 participants.

Also called NCT03078478

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,609 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03078478
  • EudraCT 2016-002801-20
Main results
  • Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial Diabetologia, 2020-04 DOI, PubMed 31984443, PMC7054369 In the PMC Open Access subset under CC BY.
Other papers using this trial's data
  • Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial Advances in therapy, 2020-05 DOI, PubMed 32306247, PMC7467476 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Denmark, Estonia, Germany, Greece, Hungary, Norway, Poland, Puerto Rico, Romania, Serbia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03078478. Randomized; no masking; primary purpose treatment. Start 2017-03-13 (actual); primary completion 2019-02-13 (actual). Results posted on 2020-03-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
Acronym
CONCLUDE
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin degludec
Intervention (Drug)
Insulin glargine
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03078478
Content hash
ac59717c52c460e29e813f3022512d1094c56123647349661fa89adba0fe3e97